Efficacy of Piroxicam Mesotherapy in Treatment of Knee Osteoarthritis: A Randomized Clinical Trial

Table 6

WOMAC score improvement in both groups during the follow-up compared to the baseline.

	Mesotherapy group	Oral therapy group	value (within groups)	value (between groups)
WOMAC^a improvement, mean ± SD^b
Pain decrement			Mesotherapy group: 0.001; Oral therapy group: 0.04
In 2 weeks	4.87 ± 3.05	1.70 ± 2.84		0.001
In 4 weeks	7.96 ± 3.19	2.32 ± 2.84		0.001
In 8 weeks	8.45 ± 4.28	3.58 ± 3.37		0.001
Stiffness decrement			Mesotherapy group: 0.001; Oral therapy group: 0.06
In 2 weeks	0.96 ± 1.16	0.19 ± 0.54		0.001
In 4 weeks	1.67 ± 1.72	0.29 ± 0.58		0.001
In 8 weeks	1.70 ± 1.69	0.61 ± 1.17		0.004
Function improvement			Mesotherapy group: 0.001; Oral therapy group: 0.03
In 2 weeks	15.03 ± 8.59	6.83 ± 9.82		0.001
In 4 weeks	23.90 ± 10.03	15.06 ± 8.60		0.001
In 8 weeks	24.61 ± 12.25	18.88 ± 9.52		0.001
Total score improvement			Mesotherapy group: 0.001; Oral therapy group: 0.04
In 2 weeks	20.86 ± 11.93	8.72 ± 4.36		0.001
In 4 weeks	33.53 ± 13.96	17.67 ± 7.11		0.001
In 8 weeks	34.76 ± 17.14	23.07 ± 10.52		0.001

^aWOMAC, Western Ontario and McMaster Universities Arthritis Index; ^bSD, standard deviation.